Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aptose Biosciences (TSE:APS)
TSX:APS
Holding TSE:APS?
Track your performance easily
APS Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$0.19 - C$3.97
Previous CloseC$0.26
Volume50.99K
Average Volume (3M)16.74K
Market Cap
C$5.08M
Enterprise Value-C$5.41M
Total Cash (Recent Filing)$8.33M
Total Debt (Recent Filing)$818.00K
Price to Earnings (P/E)―
Beta0.02
Next Earnings
Mar 25, 2025EPS Estimate
-C$0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.14
Shares Outstanding18,109,393
10 Day Avg. Volume26,930
30 Day Avg. Volume16,740
Standard Deviation0.26
R-Squared0.06
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)-3.13
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Aptose Biosciences News
PremiumCompany Announcements
Aptose Biosciences Boosts Capital with $8M Offering
PremiumCompany Announcements
Aptose Biosciences Announces $8 Million Public OfferingPremiumCompany Announcements
Aptose Biosciences Launches TUSCANY Study for AML
PremiumCompany Announcements
Aptose Biosciences Reports Q3 2024 Financial Highlights
PremiumCompany Announcements
Aptose Biosciences Advances AML Triplet TherapyOptions Prices
Currently, No data available
---
Ownership Overview
6.67% Insiders
0.01% Mutual Funds
15.43% Other Institutional Investors
77.89% Public Companies and
Individual Investors
APS FAQ
What was Aptose Biosciences’s price range in the past 12 months?
Aptose Biosciences lowest stock price was C$0.19 and its highest was C$3.97 in the past 12 months.
What is Aptose Biosciences’s market cap?
Currently, no data Available
When is Aptose Biosciences’s upcoming earnings report date?
Aptose Biosciences’s upcoming earnings report date is Mar 25, 2025 which is in 118 days.
How were Aptose Biosciences’s earnings last quarter?
Aptose Biosciences released its earnings results on Nov 08, 2024. The company reported -C$0.517 earnings per share for the quarter, beating the consensus estimate of -C$0.893 by C$0.377.
Is Aptose Biosciences overvalued?
According to Wall Street analysts Aptose Biosciences’s price is currently Overvalued.
Does Aptose Biosciences pay dividends?
Aptose Biosciences does not currently pay dividends.
What is Aptose Biosciences’s EPS estimate?
Aptose Biosciences’s EPS estimate is -C$0.49.
How many shares outstanding does Aptose Biosciences have?
Aptose Biosciences has 19,521,183 shares outstanding.
What happened to Aptose Biosciences’s price movement after its last earnings report?
Aptose Biosciences reported an EPS of -C$0.517 in its last earnings report, beating expectations of -C$0.893. Following the earnings report the stock price went up 1.852%.
Which hedge fund is a major shareholder of Aptose Biosciences?
Among the largest hedge funds holding Aptose Biosciences’s share is Carlson Capital LP. It holds Aptose Biosciences’s shares valued at N/A.
---
Aptose Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 96.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-92.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-47.65%
Trailing 12-Months
Company Description
Aptose Biosciences
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
---
APS Earnings Call
Q1 2024
0:00 / 0:00
---
APS Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Aptose Biosciences
―
Cellectar Biosciences
―
Xenetic Biosciences
―
Advaxis
―
Cyclacel Pharmaceuticals
―
Best Analysts Covering APS
1 Year
1 Year Success Rate
2/19 ratings generated profit
1 Year Average Return
-46.82%
reiterated a buy rating 7 months ago
Copying John Newman's trades and holding each position for 1 Year would result in 10.53% of your transactions generating a profit, with an average return of -46.82% per trade.
---